Virax Biolabs Group Limited (VRAX)

Virax Biolabs Group Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	4.23	3.59	9.35	0.02	0.02
Short-Term Investments	0.09	0.08	0.05	0.01	-
Cash & Short-Term Investments	4.32	3.67	9.4	0.03	0.02
Cash Growth	17.91%	-61.00%	33774.24%	57.51%	-22.06%
Accounts Receivable	-	-	-	-	0
Other Receivables	0.03	0.22	-	-	-
Receivables	0.03	0.22	-	-	0
Inventory	0.19	0.18	0.02	0.02	0.02
Prepaid Expenses	0.35	0.31	0.21	-	-
Total Current Assets	4.89	4.38	9.63	0.05	0.04
Property, Plant & Equipment	1.49	1.05	-	-	-
Other Intangible Assets	0.04	0.05	0.18	-	-
Total Assets	6.43	5.48	9.81	0.05	0.04
Accounts Payable	0.06	0.05	0.16	0.85	0.22
Accrued Expenses	0.19	0.08	0.55	0.4	0.46
Short-Term Debt	0.37	-	0.16	-	0.18
Current Portion of Leases	0.05	0.05	-	-	-
Current Unearned Revenue	-	-	0.04	-	-
Other Current Liabilities	-	-	-	0	0.02
Total Current Liabilities	0.67	0.17	0.91	1.25	0.87
Long-Term Leases	0.29	0.18	-	-	-
Total Liabilities	0.96	0.35	0.91	1.25	0.87
Common Stock	0	0	0	0	0
Retained Earnings	-24.59	-18.53	-11.79	-6.34	-4.63
Comprehensive Income & Other	30.28	23.89	20.92	5.36	3.98
Total Common Equity	5.7	5.37	9.13	-0.97	-0.65
Minority Interest	-0.23	-0.23	-0.22	-0.22	-0.18
Shareholders' Equity	5.46	5.14	8.9	-1.2	-0.83
Total Liabilities & Equity	6.43	5.48	9.81	0.05	0.04
Total Debt	0.71	0.22	0.16	-	0.18
Net Cash (Debt)	3.61	3.44	9.24	0.03	-0.16
Net Cash Growth	4.83%	-62.73%	33181.39%	-	-
Net Cash Per Share	0.97	1.72	8.69	0.03	-0.66
Filing Date Shares Outstanding	4.34	2.57	1.79	1	1
Total Common Shares Outstanding	4.34	2.57	1.55	1	0.92
Working Capital	4.22	4.21	8.73	-1.2	-0.83
Book Value Per Share	1.31	2.09	5.87	-0.98	-0.70
Tangible Book Value	5.66	5.32	8.95	-0.97	-0.65
Tangible Book Value Per Share	1.30	2.07	5.76	-0.98	-0.70
Machinery	1.49	0.9	0.01	-	-

Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q